Metformin use and improved response to therapy in esophageal adenocarcinoma-Reference-Cited by-同舟云学术

Metformin use and improved response to therapy in esophageal adenocarcinoma

Published:2012-09-05 Issue:5 Volume:52 Page:1002-1009
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Skinner Heath D.,McCurdy Matthew R.,Echeverria Alfredo E.,Lin Steven H.,Welsh James W.,O'Reilly Michael S.,Hofstetter Wayne L.,Ajani Jaffer A.,Komaki Ritsuko,Cox James D.,Sandulache Vlad C.,Myers Jeffrey N.,Guerrero Thomas M.

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/0284186X.2012.718096

Reference25 articles.

1. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer

2. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma

3. Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

4. Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals

5. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights;International Journal of Molecular Sciences;2024-03-04

2. Repurposing radiosensitising medicines for radiotherapy: an overview;BMJ Oncology;2024-01

3. Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population;Oral Oncology;2023-10

4. Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients;Frontiers in Medicine;2023-09-06

5. Metformin is a metabolic modulator and radiosensitiser in rectal cancer;Frontiers in Oncology;2023-08-03